Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to $7.3 million.

  • Biodesix's Shares Outstanding (Weighted Average) rose 1.00% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 1.00%. This contributed to the annual value of $7.3 million for FY2024, which is 60.78% up from last year.
  • As of Q3 2025, Biodesix's Shares Outstanding (Weighted Average) stood at $7.3 million, which was up 0.05% from $7.3 million recorded in Q2 2025.
  • Biodesix's 5-year Shares Outstanding (Weighted Average) high stood at $7.3 million for Q3 2025, and its period low was $1.3 million during Q1 2021.
  • For the 3-year period, Biodesix's Shares Outstanding (Weighted Average) averaged around $5.8 million, with its median value being $5.7 million (2024).
  • Data for Biodesix's Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 149.06% (in 2023) over the last 5 years.
  • Biodesix's Shares Outstanding (Weighted Average) (Quarterly) stood at $1.6 million in 2021, then skyrocketed by 34.45% to $2.1 million in 2022, then spiked by 114.94% to $4.5 million in 2023, then spiked by 60.78% to $7.3 million in 2024, then grew by 1.00% to $7.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $7.3 million in Q3 2025, compared to $7.3 million in Q2 2025 and $7.3 million in Q1 2025.